A free radical-trapping agent that has been found to be neuroprotective in stoke in animals. It has been tested in ischaemic stroke in humans and was found to reduce disability at 90 days but did not improve putcome in other respects.
In 2004, a clinical trial demonstrated the effectiveness of NXY-059 compound (another PBN derivative) in patients with ischemic stroke, even when concentrations higher than 260 [micro]M of the compound were administrated intravenously .
The recently published Cerebral Hemorrhagic and NXY-059 Treatment Trial found no relationship between prior antiplatelet use and the volume of ICH on baseline CT, ICH growth, or clinical outcome at 90 days.
The news comes at a difficult time for AstraZeneca, which was relying on established medicines such as Nexium to drive sales following the failure of clinical trials for new drugs, such as stroke drug NXY-059.